Amarin and Esperion get a chance to reinforce their lipid-lowering candidates, while a Bayer heart failure project gets a high-profile slot despite its discontinuation.
As pressure builds on the German group to explain how it will replace expiring blockbusters, executives lay out a preference for early-stage collaborations and insist…
Pfizer is said to be interested in Amarin, but the Danish group’s need for a growth injection is greater.
Day three of the biotech dog and pony show saw one pharma company that unequivocally wants and needs to buy.
Some of the big small-cap fallers, meanwhile, have been subject of M&A activity. Is this a sign of things to come in 2019?
Amarin’s fish oil formulation Vascepa impressed on hard cardiovascular endpoints, but there is confusion about worsening cholesterol in the placebo group.
Turbulence in Japan made the country’s biopharma industry a relatively safe haven – but clinical success or setbacks dictated the fortunes of most mid and small-cap…
The topline result from Amarin’s Reduce-It trial has smashed expectations, delighting shareholders and framing Vascepa as a potentially practice-changing product.
The Ascend trial failure is a blow to the fish oil theory, but Amarin insists that it does not bode ill for its big readout.